Revive Therapeutics Ltd.
RVV
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 159.80K | 243.10K | 335.40K | 206.60K | 293.20K |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 159.80K | 243.10K | 335.40K | 206.60K | 399.40K |
| Operating Income | -159.80K | -243.10K | -335.40K | -206.60K | -399.40K |
| Income Before Tax | -204.60K | -6.94M | -402.20K | -260.50K | -346.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -204.60K | -6.94M | -402.20K | -260.50K | -346.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -204.60K | -6.94M | -402.20K | -260.50K | -346.40K |
| EBIT | -159.80K | -243.10K | -335.40K | -206.60K | -399.40K |
| EBITDA | -159.80K | -243.10K | -335.40K | -206.60K | -399.40K |
| EPS Basic | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.02 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 429.30M | 423.16M | 418.56M | 418.56M | 418.56M |
| Average Diluted Shares Outstanding | 429.30M | 423.16M | 418.56M | 418.56M | 418.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |